The $165M im­munol­o­gy start­up Sheila Gu­jrathi bet on af­ter Re­cep­tos, Gos­samer is shoot­ing for an IPO

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Sheila Gu­jrathi has kept her­self busy since leav­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER